Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab in prolonging the PFS in the second-line treatment of patients with metastatic CRC after failure of an irinotecan or oxaliplatin-containing first-line regimen.
Critère d'inclusion
- Second line treatment of patients with metastatic carcinoma of colon and rectum